Your shopping cart is currently empty

BGT226 (NVP-BGT226) is a novel dual PI3K/mTOR inhibitor, targeting PI3K α, β, and γ with IC50 values of 4 nM, 63 nM, and 38 nM, respectively.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $42 | In Stock | In Stock | |
| 2 mg | $59 | In Stock | In Stock | |
| 5 mg | $98 | In Stock | In Stock | |
| 10 mg | $158 | In Stock | In Stock | |
| 25 mg | $328 | In Stock | In Stock | |
| 50 mg | $538 | In Stock | In Stock | |
| 100 mg | $818 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $115 | In Stock | In Stock |
| Description | BGT226 (NVP-BGT226) is a novel dual PI3K/mTOR inhibitor, targeting PI3K α, β, and γ with IC50 values of 4 nM, 63 nM, and 38 nM, respectively. |
| Targets&IC50 | PI3Kγ:38 nM, PI3Kα:4 nM, PI3Kβ:63 nM |
| In vitro | Growth inhibition experiment showed that BGT226 had antitumor activity. BGT226 significantly inhibited cell growth with IC50 < 20 nM. BGT226 also induced cancer cell apoptosis at nanomolar concentration, IC50 ≤ 25 nM[1][2][3]. |
| In vivo | BGT226 significantly delayed tumor growth on the transplanted tumor animal model. This effect was dose-dependent, accompanied by inhibition of p-p70 S6 kinase cytoplasmic expression and autophagy body formation[2]. |
| Synonyms | NVP-BGT226, BGT226 free base |
| Molecular Weight | 534.53 |
| Formula | C28H25F3N6O2 |
| Cas No. | 915020-55-2 |
| Smiles | COc1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(-c4ccc(N5CCNCC5)c(c4)C(F)(F)F)c3c2c1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 65 mg/mL (121.6 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (1.87 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.